Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 3/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL112571 | 0.85 | HTT (0.52) | HTTPOLBMEN1GAAKMT2A | |
| SCHEMBL10824494 | 0.79 | HTT (0.47) | HTTPOLBMEN1GAAKMT2A | |
| SCHEMBL11803532 | 0.79 | HTT (0.42) | HTTPOLBMEN1GAAKMT2A | |
| SCHEMBL9853387 | 0.77 | ALDH1A1 (0.50) | HTTPOLBMEN1GAAKMT2A | |
| SCHEMBL24629974 | 0.77 | ALDH1A1 (0.39) | HTTPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL9190577 | 0.77 | DHFR (0.35) | MEN1GAAKMT2AHSPA5DHFR | |
| SCHEMBL1187136 | 0.76 | TRPA1 (0.45) | HTTPOLBMEN1GAAKMT2A | |
| SCHEMBL13804214 | 0.76 | HTT (0.39) | HTTPOLBMEN1GAAKMT2A | |
| SCHEMBL23838393 | 0.75 | HSPA5 (0.38) | MEN1GAAKMT2AALDH1A1MAPT | |
| SCHEMBL9861293 | 0.75 | AR (0.43) | HTTPOLBMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957241-B2 | Aromatic diamine, an intermediate therefor, a method for producing the aromatic diamine, and a method for producing the intermediate therefor | SEIKA CORPORATION (JP) | 2018-05-01 | — | — | US | disclosed |
| US-20180079732-A1 | AROMATIC DIAMINE, AN INTERMEDIATE THEREFOR, A METHOD FOR PRODUCING THE AROMATIC DIAMINE, AND A METHOD FOR PRODUCING THE INTERMEDIATE THEREFOR | SEIKA CORPORATION (JP) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079732-A1 | AROMATIC DIAMINE, AN INTERMEDIATE THEREFOR, A METHOD FOR PRODUCING THE AROMATIC DIAMINE, AND A METHOD FOR PRODUCING THE INTERMEDIATE THEREFOR | WEE1, WEE2, WASF2 | HTT 3592/4885POLB 2855/4885MEN1 1436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.